Generalized Anxiety Disorder (GAD) – Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2023 To 2033 thelansis.com

Generalized anxiety disorder (GAD) is a mental health condition characterized by persistent feelings of fear, worry, and being overwhelmed. It involves excessive and unrealistic concerns about daily matters, possibly stemming from various factors such as stress, underlying medical conditions like diabetes, co-existing conditions like depression, genetic predisposition (with about a 25% likelihood among first-degree relatives), and environmental influences like childhood trauma or substance abuse. While the exact cause remains unclear, research suggests the involvement of neurotransmitter systems like noradrenaline and serotonin in the body’s stress response, with low serotonin activity and heightened noradrenergic activity potentially contributing to its development. Normal anxiety can manifest in children, typically starting with stranger anxiety around seven to nine months of age. Diagnosis of GAD may involve thyroid function tests, blood glucose monitoring, echocardiography, and toxicology screening. Treatment options primarily revolve around cognitive behavioral therapy and medications, with selective serotonin reuptake inhibitors (SSRIs) and serotonin-norepinephrine reuptake inhibitors (SNRIs) being preferred due to their ability to modulate these neurotransmitter systems. Response rates to these medications typically range from 30% to 50%. XANAX (1981) is the approved product for the treatment of Generalized anxiety disorder (GAD).
• Generalized Anxiety Disorder (GAD) impacts 6.8 million adults, constituting 3.1% of the U.S. population. However, only 43.2% of affected individuals are undergoing treatment.

Thelansis’s “Generalized Anxiety Disorder (GAD) Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2023 To 2033″ covers disease overview, epidemiology, drug utilization, prescription share analysis, competitive landscape, clinical practice, regulatory landscape, patient share, market uptake, market forecast, and key market insights under the potential Generalized Anxiety Disorder (GAD) treatment modalities options for eight major markets (USA, Germany, France, Italy, Spain, UK, Japan, and China).

KOLs insights of Generalized Anxiety Disorder (GAD) across 8 MM market from the centre of Excellence/ Public/ Private hospitals participated in the study. Insights around current treatment landscape, epidemiology, clinical characteristics, future treatment paradigm, and Unmet needs.
Generalized Anxiety Disorder (GAD) Market Forecast Patient Based Forecast Model (MS. Excel Based Automated Dashboard), which Data Inputs with sourcing, Market Event, and Product Event, Country specific Forecast Model, Market uptake and patient share uptake, Attribute Analysis, Analog Analysis, Disease burden, and pricing scenario, Summary, and Insights.
Thelansis Competitive Intelligence (CI) practice has been established based on a deep understanding of the pharma/biotech business environment to provide an optimized support system to all levels of the decision-making process. It enables business leaders in forward-thinking and proactive decision-making. Thelansis supports scientific and commercial teams in seamless CI support by creating an AI/ ML-based technology-driven platform that manages the data flow from primary and secondary sources.
Read more: Generalized Anxiety Disorder (GAD) – Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2023 To 2033
Tags: Generalized Anxiety Disorder (GAD), Generalized Anxiety Disorder (GAD) market outlook, Generalized Anxiety Disorder (GAD) competitive landscape, Generalized Anxiety Disorder (GAD) market forecast, Thelansis, Primary market research, KOL insights, Competitive Intelligence (CI)